- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06384807
Et fase 1/2-studie af PBI-410 i avancerede solide tumorer
En fase 1/2, først i human, dosiseskalering og dosisudvidelsesundersøgelse af PBI-410 hos deltagere med avancerede solide tumorer
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510, a Trop-2 directed antibody-drug conjugate (ADC), in participants with previously treated, advanced solid tumors. The study comprises 2 parts: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion. The Phase 1 will investigate the safety and tolerability of BHV-1510 given in monotherapy and given in combination with cemiplimab and identify one or more recommended doses for expansion (RDEs) and the maximum-tolerated dose (MTD) (if one exists). Once the RDE has been established, Phase 2 will open to investigate the preliminary efficacy of BHV-1510 in signal-finding expansion cohorts.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Chief Medical Officer
- Telefonnummer: 203-404-0410
- E-mail: clinicaltrials@biohavenpharma.com
Studiesteder
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Rekruttering
- Site-113
-
La Jolla, California, Forenede Stater, 92093
- Rekruttering
- Site-112
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Site-111
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20016
- Rekruttering
- Site-114
-
-
Florida
-
Miami, Florida, Forenede Stater, 33176
- Rekruttering
- Site-103
-
Orlando, Florida, Forenede Stater, 32827
- Rekruttering
- Site-105
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Site-115
-
-
Georgia
-
Augusta, Georgia, Forenede Stater, 30912
- Rekruttering
- Site-110
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48201
- Rekruttering
- Site-109
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63108
- Afsluttet
- Site-101
-
-
New York
-
New York, New York, Forenede Stater, 10021
- Rekruttering
- Site-117
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73117
- Rekruttering
- Site-116
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Rekruttering
- Site-108
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Site-107
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75231
- Rekruttering
- Site-104
-
-
Utah
-
West Valley City, Utah, Forenede Stater, 84119
- Rekruttering
- Site-106
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Site-102
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
-
Male or female participants aged ≥18 years.
-
Unresectable, incurable, locally advanced or metastatic epithelial-origin solid tumor that is refractory to standard therapies, or has no approved standard therapies, or no approved standard therapies at its current treatment stage. If applicable to the tumor type, participants must have received platinum-based chemotherapy, standard of care immunotherapy, and standard of care targeted therapies.
-
Measurable disease (per RECIST 1.1).
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
-
Participants have adequate hematologic, renal, liver, and coagulation function as defined by the following (blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility):
- Hemoglobin ≥9 g/dL
- Absolute neutrophil count >1,500/mm3; participants with known Duffy null phenotype who have absolute neutrophil count ≥1,200/mm3 may be enrolled
- Platelets >100,000/mm3
- Creatinine clearance ≥50 mL/min measured or estimated using the Cockcroft-Gault formula; 24-hour urine collection is allowed, but not required.
- Total bilirubin ≤1.5 × upper limit of normal (ULN); participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)
- Alkaline phosphatase <2.5×ULN (or ≤5×ULN for participants with hepatic and/or bone metastases)
- International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN
- Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
-
Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
BHV-1510 in Combination with specific inclusion criteria:
- histologically or cytologically documented advanced (locally, recurrent, inoperable, cannot betreated with curative intent) or metastatic cancer including Endometrial Carcinoma that is confirmed as proficient mismatch repair (pMMR)
- received ≤ 2 prior lines of systemic anti-cancer therapy and at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease.
Key Exclusion Criteria:
- Women who are pregnant or lactating.
- Clinically significant intercurrent disease.
- Has symptomatic brain metastases or has had any radiation or surgery for brain metastases within 4 weeks of C1D1.
- Has clinically significant corneal disease.
- Requires supplemental oxygen for daily activities.
- Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.
- Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on imaging at Screening.
- Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone and visceral metastasis therapy. Any major surgical procedure within 6 weeks prior to C1D1.
- History of severe hypersensitivity reactions to other monoclonal antibodies or either the drug substances or inactive ingredients of BHV-1510.
- Has current or previously treated leptomeningeal carcinomatosis.
- Use of OAP1B1 and OATP1B3 inhibitors within 14 days prior to starting trial.
BHV-1510 in Combination Specific Exclusion Criteria:
- Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling.
- Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
- Prior allogeneic stem cell or solid organ transplantation.
- Patients with history of myocarditis.
- Presence of cardiovascular disease
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: BHV-1510 Monoterapi dosiseskalering
|
BHV-1510 will be administered on Day 1 every 3 weeks
Andre navne:
BHV-1510 will be administered on Day 1 every 2 weeks
Andre navne:
BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks
Andre navne:
|
|
Eksperimentel: BHV-1510 i kombination med Cemiplimab dosiseskalering
|
BHV-1510 will be administered on Day 1 every 3 weeks
Andre navne:
BHV-1510 will be administered on Day 1 every 2 weeks
Andre navne:
BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks
Andre navne:
cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Phase 1: Number of patients with adverse events (AEs)
Tidsramme: Through study completion, estimated as an average of 47 months
|
Description: Incidence and severity of AEs, serious adverse events (SAEs) and dose limiting toxicities (DLTs). Severity of AEs will be assessed according to the NCI CTCAE v5.0. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)
Tidsramme: Approximately 15 months
|
Based on tolerability and preliminary antitumor activity. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Approximately 15 months
|
|
Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months
|
Incidence and severity of AEs, SAEs and DLTs. Severity of AEs will be assessed according to the NCI CTCAE v5.0 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Fase 1 og 2: Maksimal plasmakoncentration (CMAX) af BHV-1510, total antistof og nyttelast (BHC-0080269)
Tidsramme: Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
|
|
Fase 1 og 2: Område under koncentrationen versus tidskurve fra slutningen af infusion til den sidste målbare koncentration (AUCLAST) af BHV-1510, total antistof og nyttelast
Tidsramme: Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
|
|
Fase 1 og 2: Område under koncentrationen versus tidskurve over doseringsintervallet (AUCTAU) af BHV-1510, total antistof og nyttelast
Tidsramme: Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
|
|
Fase 1 og 2: Elimination Half-Life (T1/2) af BHV-1510, total antistof og nyttelast
Tidsramme: Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
|
|
Fase 1 og 2: Trough-koncentration (CTROUGH) af BHV-1510, total antistof og nyttelast
Tidsramme: Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
Op til 8 tidspunkter, men ikke overstiger, 22 dage i cykler 1 og 3
|
|
|
Fase 2: Effekter af BHV-1510 monoterapi og nyttelast på QTC-intervallet ved hjælp af Fridericias korrektionsmetode (QTCF) og på andre EKG-parametre (hjerterytme [HR], PR og QRS-interval)
Tidsramme: Ca. 15 måneder
|
Ca. 15 måneder
|
|
|
Fase 1 og 2: Areal under koncentrations-kurven i forhold til tid ekstrapoleret til uendelig (AUCinf) for BHV-1510, totalt antistof og payload
Tidsramme: Op til 8 tidspunkter, men ikke overstigende 22 dage i Cyklus 1
|
Op til 8 tidspunkter, men ikke overstigende 22 dage i Cyklus 1
|
|
|
Fase 1 og 2: Total kropsclearance (CL) efter IV-administration eller tilsyneladende total kropsclearance (CL/F) efter SC-administration af BHV-1510 og total antistof
Tidsramme: Op til 8 tidspunkter, dog ikke overstigende 22 dage i cyklus 1 og 3
|
Op til 8 tidspunkter, dog ikke overstigende 22 dage i cyklus 1 og 3
|
|
|
Fase 1 og 2: Procentvis bionedbrydelighed (%F) efter subkutan administration af BHV-1510 og total antistof
Tidsramme: Op til 8 tidspunkter, men ikke overskridende 22 dage i cyklus 1 og 3
|
Op til 8 tidspunkter, men ikke overskridende 22 dage i cyklus 1 og 3
|
|
|
Fase 1 og 2: Distributionsvolumen ved steady state (Vss) efter IV-administration eller tilsyneladende distributionsvolumen ved steady state (Vss/F) efter SC-administration af BHV-1510 og total antistof
Tidsramme: Op til 8 tidspunkter, men ikke overstigende 22 dage i cyklus 1 og 3
|
Op til 8 tidspunkter, men ikke overstigende 22 dage i cyklus 1 og 3
|
|
|
Phase 1: ORR
Tidsramme: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1: Duration of Response (DoR)
Tidsramme: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1 and 2: Immunogenicity of BHV-1510
Tidsramme: Through study completion, estimated as an average of 47 months
|
Incidence of ADA at baseline and post-treatment, including ADA titer |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Disease control rate (DCR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Progression free survival (PFS) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Overall survival (OS) for BHV-1510 for monotherapy and in combination with cemiplimab
Tidsramme: Through study completion, estimated as an average of 47 months
|
OS is defined as the time period from the start of administration to death due to any cause |
Through study completion, estimated as an average of 47 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Chief Medical Officer, Biohaven Pharmaceuticals, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- BHV1510-101 (PBI-410-101)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .